Tue, Mar 4, 12:43 PM (54 days ago)
Instil Bio, Inc. (TIL) reported a net loss of $74.1 million for the fiscal year ended December 31, 2024, a significant decrease from $156.1 million in 2023. The company’s total operating expenses dropped to $73.5 million from $159.2 million, largely due to reduced research and development costs following strategic restructuring. The lead product candidate, AXN-2510/IMM2510, is a bispecific antibody targeting PD-L1 and VEGF for solid tumors and is currently in clinical trials in collaboration with ImmuneOnco. The company has $115.1 million in cash, cash equivalents, and marketable securities, expected to sustain operations through 2026. Instil is shifting focus from cell therapies to advancing AXN-2510 and exploring additional therapeutic acquisitions. Key risks include reliance on third-party manufacturers, competition from established firms, regulatory challenges, and potential changes in U.S.-China relations affecting their collaboration. The market position remains uncertain, with significant competition in the biopharmaceutical sector, particularly in oncology. The company’s future success hinges on effective clinical trial outcomes, regulatory approvals, and commercialization strategies.